RadNet, Inc. logo RDNT - RadNet, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
1
BUY 8
HOLD 2
SELL 0
STRONG
SELL
0
| PRICE TARGET: $65.00 DETAILS
HIGH: $65.00
LOW: $65.00
MEDIAN: $65.00
CONSENSUS: $65.00
DOWNSIDE: 9.31%

Stock News

New Study Shows DeepHealth AI Could Help Avoid Nearly One in Five Prostate Biopsies

New Study Shows DeepHealth AI Could Help Avoid Nearly One in Five Prostate Biopsies

SOMERVILLE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced new findings published in European Radiology supporting that AI applications within DeepHealth's Prostate MR Solution1 could help clinicians decide more confidently which men may need a prostate biopsy, particularly when MRI findings are uncertain.2 Prostate cancer is the second most commonly diagnosed cancer among men worldwide, with an estimated 1.55 million new cases in 2024.3 MRI helps clinicians assess whether prostate cancer may be present, but some findings remain uncertain.4   A biopsy involves collecting small tissue samples to check for cancer and, if found, assess its grade.

Oct 08, 2026 02:00 AM • globenewswire.com
RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026

RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026

LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026 at 07:45 a.m. Eastern Time.

Sep 09, 2026 02:00 AM • globenewswire.com
RadNet to Host Free Prostate Cancer Webinar on September 19, 2026

RadNet to Host Free Prostate Cancer Webinar on September 19, 2026

LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 442 outpatient imaging centers and a premier developer of radiology digital health solutions, today announced it will host a free webinar for patients and the general public on Saturday, September 19, 2026, in support of Prostate Cancer Awareness Month.

Sep 09, 2026 02:00 AM • globenewswire.com
RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026

RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026

LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Greg Sorensen, Executive Vice President and Chief Strategy Officer, will be presenting at the Jefferies Healthcare Services Conference on Tuesday, September 15, 2026 at 9:10 a.m.

Sep 08, 2026 02:00 AM • globenewswire.com
Head to Head Contrast: RadNet (NASDAQ:RDNT) and Oncology Institute (NASDAQ:TOI)

Head to Head Contrast: RadNet (NASDAQ:RDNT) and Oncology Institute (NASDAQ:TOI)

Oncology Institute (NASDAQ: TOI - Get Free Report) and RadNet (NASDAQ: RDNT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Analyst Ratings This is a summary of current ratings

Aug 24, 2026 12:18 AM • defenseworld.net
RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges

RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges

Total Company Revenue increased 25.0% to a quarterly record of $622.7 million in the second quarter of 2026 from $498.2 million in the second quarter of 2025 Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 56.5% to a quarterly record of $32.4 million in the second quarter of 2026 from $20.7 million in the second quarter of 2025; Annual Recurring Revenue ( 4) (ARR) increased from $53.5 million at June 30, 2025 to $105.5 million at June 30, 2026 and sequentially increased from $96.9 million at March 31, 2026 Total Company Adjusted EBITDA ( 1) was a quarterly record of $99.7 million in the second quarter of 2026 as compared with $81.2 million in the second quarter of 2025, an increase of 22.7%; Digital Health reportable segment Adjusted EBITDA ( 1) was $2.5 million in the second quarter of 2026 compared with $3.4 million in the second quarter of 2025, the result of continued infrastructure investments to fuel growth Imaging Center Segment Adjusted EBITDA ( 1) margin increased by 17 basis points to 16.1% in the second quarter of 2026 from 16.0% in the second quarter of 2025 Adjusting for unusual or one-time items, Adjusted Earnings ( 3) was $23.2 million and Adjusted Earnings Per Share ( 3) was $0.29 for the second quarter of 2026 as compared with Adjusted Earnings ( 3) of $25.7 million and Adjusted Earnings Per Share ( 3) of $0.34 for the second quarter of 2025   As a percentage of total procedural volumes, advanced imaging increased by 238 basis points to 29.9% in the second quarter of 2026 from 27.5% in the second quarter of 2025 In the second quarter of 2026, aggregate advanced imaging (MRI, CT and PET/CT) procedural volumes increased 21.2% and same-center advanced imaging procedural volumes increased 9.6% as compared with the second quarter of 2025 As of June 30, 2026, balance sheet cash was $726.3 million and Net Debt to Adjusted EBITDA ( 1) Ratio ( 5 ) was 1.8x RadNet revises full-year 2026 Imaging Center guidance levels with increases to Revenue, Adjusted EBITDA ( 1) and Free Cash Flow ( 2 ) and reaffirms all Digital Health guidance ranges LOS ANGELES, Aug. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet” or the “Company”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 442 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2026. Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “The Imaging Center and Digital Health reportable operating segments continue to demonstrate strong growth and achieve record quarterly results.

Aug 09, 2026 12:00 PM • globenewswire.com

Price Targets